Stay updated on Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.

Latest updates to the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedTaiwan site listing now specifies Taoyuan City rather than Taoyuan, clarifying the exact location.SummaryDifference0.0%

- Check16 days agoChange DetectedRevision: v3.5.3 now appears, replacing Revision: v3.5.2. This indicates a version update to the page’s documentation or release notes rather than changes to study data or core content.SummaryDifference0.0%

- Check24 days agoChange DetectedThe page’s software/site revision indicator was updated from v3.5.0 to v3.5.2, with no visible changes to the study information.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now shows Revision: v3.5.0, replacing the previous revision v3.4.3.SummaryDifference0.0%

- Check67 days agoChange DetectedThe revision tag was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

- Check89 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Lebrikizumab Long-term Safety Efficacy AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Long-term Safety Efficacy AD Clinical Trial page.